TD Cowen assumed coverage on shares of Sionna Therapeutics (NASDAQ:SION – Free Report) in a research note published on Tuesday, MarketBeat.com reports. The brokerage issued a buy rating on the stock.
Other equities research analysts have also recently issued reports about the stock. Guggenheim assumed coverage on shares of Sionna Therapeutics in a research report on Tuesday. They set a “buy” rating and a $45.00 price objective for the company. Stifel Nicolaus initiated coverage on shares of Sionna Therapeutics in a report on Tuesday. They set a “buy” rating and a $32.00 price target for the company.
Check Out Our Latest Analysis on SION
Sionna Therapeutics Price Performance
About Sionna Therapeutics
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Read More
- Five stocks we like better than Sionna Therapeutics
- What is the Dow Jones Industrial Average (DJIA)?
- GitLab: Get In While It’s Down—Big Rebound Ahead
- What Are Earnings Reports?
- Tesla Stock: Finding a Bottom May Take Time
- Best Stocks Under $10.00
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
